Effect of Spironolactone in Resistant Arterial Hypertension : A Randomized, Double-Blind, Placebo-Controlled Trial (ASPIRANT-EXT)

VÁCLAVÍK, Jan, Richard SEDLÁK, Jiří JARKOVSKÝ, Eva KOCIÁNOVÁ a Miloš TÁBORSKÝ. Effect of Spironolactone in Resistant Arterial Hypertension : A Randomized, Double-Blind, Placebo-Controlled Trial (ASPIRANT-EXT). Medicine. Philadelphia: Lippincott Williams & Wilkins, 2014, roč. 93, č. 27, s. "e162", 9 s. ISSN 0025-7974. Dostupné z: https://dx.doi.org/10.1097/MD.0000000000000162.

Základní údaje

• Originální název: Effect of Spironolactone in Resistant Arterial Hypertension : A Randomized, Double-Blind, Placebo-Controlled Trial (ASPIRANT-EXT)
• Název anglicky: Effect of Spironolactone in Resistant Arterial Hypertension : A Randomized, Double-Blind, Placebo-Controlled Trial (ASPIRANT-EXT)
• Autoři: VÁCLAVÍK, Jan (203 Česká republika), Richard SEDLÁK (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, garant, domácí), Eva KOCIÁNOVÁ (203 Česká republika) a Miloš TÁBORSKÝ (203 Česká republika).
• Vydání: Medicine, Philadelphia, Lippincott Williams & Wilkins, 2014, 0025-7974.

Další údaje

• Originální jazyk: čeština
• Typ výsledku: Článek v odborném periodiku
• Obor: 30201 Cardiac and Cardiovascular systems
• Stát vydavatele: Spojené státy
• Utajení: není předmětem státního či obchodního tajemství
• Impakt faktor: Impact factor: 5.723
• Kód RIV: RIV/00216224:14110/14:00078887
• Organizační jednotka: Lékařská fakulta
• Doi: http://dx.doi.org/10.1097/MD.0000000000000162
• UT WoS: 000346406500011
• Klíčová slova anglicky: LOW-DOSE SPIRONOLACTONE; BLOOD-PRESSURE; REFRACTORY HYPERTENSION; PRIMARY ALDOSTERONISM; EUROPEAN-SOCIETY; EFFICACY; DENERVATION; EPLERENONE; PREVALENCE; ANTAGONISM
• Štítky: EL OK
• Příznaky: Mezinárodní význam, Recenzováno

Anotace

This study was designed to assess the effect of the addition of low-dose spironolactone on blood pressure (BP) in patients with resistant arterial hypertension. Patients with office systolic blood pressure (SBP) >140 mm Hg or diastolic blood pressure (DBP) >90 mm Hg despite treatment with at least 3 antihypertensive drugs, including a diuretic, were enrolled in this double-blind, placebo-controlled, multicentre trial. One hundred sixty-one patients in outpatient internal medicine departments of 6 hospitals in the Czech Republic were randomly assigned to receive 25 mg of spironolactone (N = 81) or a placebo (N = 80) once daily as an add-on to their antihypertensive medication, using simple randomization. This study was registered with ClinicalTrials.gov, number NCT00524615. Analyses were done with 150 patients who finished the follow-up (74 in the spironolactone and 76 in the placebo group). At 8 weeks, BP values were decreased more by spironolactone, with differences in mean fall of SBP of -9.8, -13.0, -10.5, and -9.9 mm Hg (P < 0.001 for all) in daytime, nighttime, and 24-hour ambulatory BP monitoring and in the office. The respective DBP differences were -3.2, -6.4, -3.5, and -3.0 mm Hg (P < 0.013, P < 0.001, P = 0.005, and P = 0.003). Adverse events in both groups were comparable. The office SBP goal <140 mm Hg at 8 weeks was reached in 73% of patients using spironolactone and 41% using placebo (P = 0.001). Spironolactone in patients with resistant arterial hypertension leads to a significant decrease of both SBP and DBP and markedly improves BP control.

Anotace anglicky

This study was designed to assess the effect of the addition of low-dose spironolactone on blood pressure (BP) in patients with resistant arterial hypertension. Patients with office systolic blood pressure (SBP) >140 mm Hg or diastolic blood pressure (DBP) >90 mm Hg despite treatment with at least 3 antihypertensive drugs, including a diuretic, were enrolled in this double-blind, placebo-controlled, multicentre trial. One hundred sixty-one patients in outpatient internal medicine departments of 6 hospitals in the Czech Republic were randomly assigned to receive 25 mg of spironolactone (N = 81) or a placebo (N = 80) once daily as an add-on to their antihypertensive medication, using simple randomization. This study was registered with ClinicalTrials.gov, number NCT00524615. Analyses were done with 150 patients who finished the follow-up (74 in the spironolactone and 76 in the placebo group). At 8 weeks, BP values were decreased more by spironolactone, with differences in mean fall of SBP of -9.8, -13.0, -10.5, and -9.9 mm Hg (P < 0.001 for all) in daytime, nighttime, and 24-hour ambulatory BP monitoring and in the office. The respective DBP differences were -3.2, -6.4, -3.5, and -3.0 mm Hg (P < 0.013, P < 0.001, P = 0.005, and P = 0.003). Adverse events in both groups were comparable. The office SBP goal <140 mm Hg at 8 weeks was reached in 73% of patients using spironolactone and 41% using placebo (P = 0.001). Spironolactone in patients with resistant arterial hypertension leads to a significant decrease of both SBP and DBP and markedly improves BP control.